# Increasing Natural Killer Cell Activity of Mineral Nanomaterial ALP1018 in Healthy Adults: A Randomized, Double-Blind, Placebo Comparative Clinical Trial

## TL;DR

This clinical trial found that a nanomaterial supplement called ALP1018 increased natural killer cell activity in healthy adults without causing adverse effects.

## Contribution

The study demonstrates that ALP1018, a nanomaterial containing iron and zinc, can safely enhance natural killer cell activity in healthy individuals.

## Key findings

- ALP1018 increased natural killer (NK) cell activity in the test group compared to baseline after 8 weeks.
- In participants affected by COVID-19, NK cell activity in the test group significantly increased at 4 and 8 weeks.
- No significant differences in cytokine levels or adverse effects were observed between the test and placebo groups.

## Abstract

This randomized, double-blind, placebo comparative clinical trial aimed to determine the immune-enhancing effects and safety of a nanomaterial with iron and zinc (ALP1018) in healthy adults. Participants who met the inclusion criteria were recruited for this study (n = 80) and randomly assigned to either the test group (n = 40), which was given Alp1018 in capsule form, or the placebo group (n = 40), which was given crystal cellulose capsules of identical appearance, weight, and flavor for 8 weeks. Compared to baseline, natural killer (NK) cell activity (%) increased in the test group after 8 weeks, although there were no changes in the placebo group. Furthermore, in the subgroup analysis of Coronavirus disease 2019 (COVID-19) affected participants, significantly increased NK cell activity was observed in the test group at 4 (p < 0.05) and 8 weeks (p < 0.05). No significant differences were observed in cytokine levels between the two groups. ALP1018 supplementation appeared to enhance immune function by improving NK cell activity without adverse effects in healthy adults.